GlaxoSmithKline takes TB vaccine to Phase IIb

BCG (Bacille Calmette-Guérin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline ($GSK), which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya, Standard Digital reports. The multicountry trials are also taking place in South Africa and Zambia and will evaluate the safety of the candidate. The Kenyan arm is expected to enroll at least 450 Kenyans aged 18 to 50, and is expected to be completed in 2018. The goal is to develop a vaccine that will prevent the progression of latent TB to active TB. More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.